Immunotherapy cancer drugs can cause a potentially vision-robbing side effect. In a new report, Michigan Medicine experts discuss the risks and what oncologists should know.
FDA approves CAR T-cell therapy, a state-of-the-art immune-therapy trial to target childhood leukemia. Mott is the only certified treatment center in Michigan and one of a select few in the country to offer it.
Michigan Medicine experts discuss whether active surveillance — close monitoring without immediate treatment — could reduce overtreatment for some thyroid, prostate and breast cancer patients.
As more biomarker-based studies open, such testing will increase opportunities to match patients with clinical trials.
U-M researchers report a new understanding of the enzyme P-Rex1, a step toward novel drug therapies to help stop the spread of certain cancers.